Indication of 99mTc-MDP bone scan after 123I-MIBG scintigraphy in patients with neuroblastoma
Open Access
- 12 January 2019
- journal article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (4)
Abstract
123I-MIBG (metaiodobenzylguanidine) scintigraphy and 99mTc-MDP bone scintigraphy (bone scan) are widely used in diagnosis and staging of NB. Consecutively using both methods lead to overall radiation exposure. As most of the patients need additional anesthesia to perform these diagnostic procedures, which accordingly increase the side effect, workload and expenditure. To minimize the exposure, side effect, workload and expenditure, we set the tasks to optimize the diagnostic algorithm. Determine the indications of bone scan after 123I-MIBG scintigraphy. Materials and Methods: 129 patients with NB were included in retrospective study who underwent both diagnostic procedures at interval of less than 30 days at the stage of initial diagnostic procedure using standard protocols. Out of 83 MIBG positive patients bone scan was able to detect metastatic lesions only in 48 patients. However, bone scan had revealed metastatic lesions in 3 out of 14 MIBG-negative patients. Bone scan is indicated only in MIBG-negative neuroblastoma patients; and in cases where the MIBG uptake cannot be determined for example after operative treatment or after starting of chemotherapy.Keywords
This publication has 19 references indexed in Scilit:
- Neuroblastoma and nephroblastoma: a radiological reviewCancer Imaging, 2015
- Neuroblastoma: Molecular Pathogenesis and TherapyAnnual Review of Medicine, 2015
- Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group ProjectRadiology, 2011
- Epidemiology of childhood cancerCancer Treatment Reviews, 2010
- Neuroblastoma: Biology, Prognosis, and TreatmentHematology/Oncology Clinics of North America, 2010
- 123I-MIBG Scintigraphy and 18F-FDG PET in NeuroblastomaJournal of Nuclear Medicine, 2009
- The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trialPediatric Blood & Cancer, 2007
- From the Archives of the AFIPRadioGraphics, 2002
- Metastatic Sites in Stage IV and IVS Neuroblastoma Correlate With Age, Tumor Biology, and SurvivalJournal of Pediatric Hematology/Oncology, 1999